SLC22A17

Across TCGA pan-cancer cohorts, SLC22A17 RNA differs between tumor and matched normal tissue in 13 of 18 cancer types tested, making tumor–normal expression one of SLC22A17’s most consistent transcriptional readouts.

The strongest signal is observed in kidney chromophobe (KICH), where SLC22A17 RNA is repressed in tumor relative to normal tissue. In most cancer types SLC22A17 is over-expressed in tumor, although a few such as KICH and COAD show the opposite, repressed pattern.

KICH, COAD, and BLCA are the cancer types where SLC22A17 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in SLC22A17 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KICH	Female	III,IV	−4.353	<.001	11	view →
COAD	Female	II,III,IV	−1.379	<.001	10	view →
BLCA	All	IV	−1.364	.005	8	view →
UCEC	All	All	−1.812	<.001	6	view →
STAD	All	All	−1.364	<.001	6	view →
THCA	Male	All	−0.762	.003	4	view →
BRCA	Female	All	−0.552	<.001	4	view →
CHOL	All	All	+1.044	.005	3	view →
READ	Female	All	−2.094	.005	2	view →
PRAD	All	All	−0.860	<.001	2	view →
BRCA	All	IV	+0.264	.041	2	view →
LUSC	All	III,IV	−0.641	.049	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 13 lineages.

SLC22A17–KICH

Open the KICH breakdown →